iron deficiency anemia
Conditions
Interventions
Accelerating group:Iron sucrose injection 200mg intravenously daily until infusion of the estimated total iron deficiency dose
Conventional group:Iron sucrose injection 200mg intravenously, administered 3 times a week until the estimated total iron deficiency dose was transfused
Sponsors
the First People’s Hospital of Xining
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: (1) Age =18 years old; (2) Able to sign informed consent; (3) History of oral iron intolerance or no response; (4) Individuals with moderate to severe iron deficiency anemia caused by different etiologies, such as chronic inflammation, gynecological diseases, gastrointestinal diseases, heart failure, and insufficient iron intake.
Exclusion criteria
Exclusion criteria: (1) Anemia caused mainly by factors other than iron deficiency (such as megaloblastic anemia, hemolytic anemia); (2) Allergic to iron sucrose injection in the past; (3) Pregnant and lactating women; (4) Serum ferritin (SF) > 700ng/mL and/or TSAT > 50%; (5) Patients with other serious diseases (including active infection, active bleeding, malignancy, hematologic malignancy, CKD, severe heart failure (NYHA Class III or IV), severe liver disease); (6) Patients who had received blood transfusion and erythropoietin treatment within 30 days before enrollment; (7) Patients who had received intravenous iron infusion within 10 days before enrollment; (8) Patients who underwent surgery 30 days before enrollment or who might require general anesthesia during the trial. (9) Any other laboratory abnormality, medical condition, or mental disorder that the investigator believes may jeopardize the treatment of the subject's disease or may cause the subject to be unable to comply with the study requirements.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| hemoglobin;Complex cardiovascular adverse event incidence; | — |
Secondary
| Measure | Time frame |
|---|---|
| Absolute reticulocyte count;Serum iron;ferritin;The time of the first composite cardiovascular adverse event;Number of allergic patients;Number of cases of phlebitis and rash; | — |
Countries
China
Contacts
Public ContactXiaolong YUAN
the First People’s Hospital of Xining
Outcome results
None listed